Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia
WE Aulitzky, C Peschel, D Despres, J Aman… - Annals of …, 1993 - Springer
It was the aim of this study to investigate the antileukemic activities of recombinant interferon
beta (rIFN beta) in chronic-phase CML in vitro and in vivo. Nine patients in the early chronic …
beta (rIFN beta) in chronic-phase CML in vitro and in vivo. Nine patients in the early chronic …
Use of interferon in the treatment of chronic myelogenous leukemia.
M Talpaz - Seminars in oncology, 1994 - europepmc.org
In a series of studies spanning 14 years, investigators from MD Anderson Cancer Center
(Houston, TX) documented the activity of interferon-alfa (IFN-alpha) in chronic myelogenous …
(Houston, TX) documented the activity of interferon-alfa (IFN-alpha) in chronic myelogenous …
Interferon alpha alone is able to cure chronic myeloid leukemia in a small subset of patients despite the persistence of leukemic cells: experience of long follow up …
FX Mahon, MP Fort, G Etienne, G Marit, N Milpied… - Blood, 2010 - Elsevier
Abstract 2299 Before the imatinib era and besides allogeneic hematopoietic stem cell
transplantation (HSCT), interferon alpha (IFN) was an alternative therapeutic option to treat …
transplantation (HSCT), interferon alpha (IFN) was an alternative therapeutic option to treat …
Interferon alfa-2b in acute-and chronic-phase chronic myelogenous leukaemia: initial response and long-term results in 54 patients
N Niederle, T Moritz, O Kloke, U Wandl, D May… - European Journal of …, 1991 - Elsevier
Fifty-four patients with Ph 1-positive chronic myelogenous leukaemia (CML)(48 with chronic-
phase and six acute-phase disease) were treated with interferon alfa-2b subcutaneously …
phase and six acute-phase disease) were treated with interferon alfa-2b subcutaneously …
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
HM Kantarjian, FJ Giles, SM O'Brien… - … /oncology clinics of North …, 1998 - Elsevier
The prognosis for patients with chronic myelogenous leukemia (CML) has changed
markedly since 1856, when the use of arsenicals (Fowler's solution) was first advocated in …
markedly since 1856, when the use of arsenicals (Fowler's solution) was first advocated in …
Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase …
H Ozer, SL George, CA Schiffer, K Rao, PN Rao… - 1993 - ashpublications.org
We investigated whether recombinant alpha 2b interferon (r alpha 2bIFN) would reduce the
proportion of bone marrow Philadelphia chromosome (Ph) cells in chronic-phase chronic …
proportion of bone marrow Philadelphia chromosome (Ph) cells in chronic-phase chronic …
Cytogenetic and breakpoint cluster region (bcr) changes in chronic myelogenous leukaemia treated with low-dose alpha interferon
R Aitchison, E McSweeney, L Butler… - European Journal of …, 1991 - Elsevier
THERE is continuing interest in the role of alpha interferon in the treatment of chronic
myelogenous leukaemia (CML), both because it is an effective agent for disease control and …
myelogenous leukaemia (CML), both because it is an effective agent for disease control and …
A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia
R Ohno, Kouseisho Leukemia Study Group - Leukemia Research, 1998 - infona.pl
To evaluate the long-term effectiveness of interferon-α (IFN-α) therapy in patients with
chronic myelogenous leukemia (CML) in chronic phase, we examined the updated …
chronic myelogenous leukemia (CML) in chronic phase, we examined the updated …
A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia
K Ohnishi, M Tomonaga, N Kamada, K Onozawa… - Leukemia research, 1998 - Elsevier
To evaluate the long-term effectiveness of interferon-α (IFN-α) therapy in patients with
chronic myelogenous leukemia (CML) in chronic phase, we examined the updated …
chronic myelogenous leukemia (CML) in chronic phase, we examined the updated …
Interferon alpha--the drug of choice for patients with chronic myeloid leukemia
H Klamova, A Vitek, K Michalova… - Casopis Lekaru …, 1998 - europepmc.org
Background The conventional, or standard, treatment of chronic myeloid leukaemia (CML)
with hydroxyurea and busulfan has no marked influence on its course or duration. Interferon …
with hydroxyurea and busulfan has no marked influence on its course or duration. Interferon …